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position of the maze, the material of the apparatus, white noise 
level, or change in laboratories, did not affect the OTT in a re-test 
situation with 24 h interval time (Rodgers et al., 1997; Calzavara 
et al., 2005). Moreover, variation of the time span of the first trial 
results in often contradictory data across the literature (File et al., 
1993; Holmes and Rodgers, 1999; Dal-Col et al., 2003; Calzavara 
et al., 2005).
It has been suggested that the prior experience of the EPM causes 
a shift of the emotional state of the animal and the acquisition of 
a phobic state instead of an unconditioned anxiety response (File 
et al., 1993; Cruz-Morales et al., 2002). As BDZs are anxiolytic but 
not effective in phobic-like states this might explain the lack of 
reactivity in the second EPM trial (Lister, 1987; File, 1993; File and 
Zangrossi Jr., 1993). This emotional shift has been a main focus 
of the research concerning the OTT and the re-test reliability of 
the EPM test as the accumulated literature indicates that a second 
trial appears to measure fear rather than anxiety (Pawlak et al., 
in press). These changes in the behavioral profile have also been 
assessed statistically using factor analysis to assign measurements 
taken to a number of factors underlying concepts such as anxiety, 
risk assessment, or fear. The analysis of trial and re-trial revealed 
IntroductIon
The elevated plus-maze (EPM) is one of the most commonly used 
models in behavioral neuroscience to evaluate rodent anxiety-
related behaviors. The EPM is validated for rats (Pellow et al., 1985) 
and mice (Lister, 1987; for review see Carobrez and Bertoglio, 2005; 
Walf and Frye, 2007; Pawlak et al., 2008).
Even though the EPM paradigm has been extensively used there 
are still aspects which remain inconclusive, most prominently the 
phenomenon of “one-trial tolerance” (OTT), first described by File 
et al. (1990). The OTT is characterized by a marked reduction in 
the anxiolytic-like effect of benzodiazepines (BDZ) during a re-
exposure to the apparatus after only one previous EPM experience 
(File and Zangrossi Jr., 1993; Gonzalez and File, 1997; Frussa-Filho 
et al., 1999; Pereira et al., 1999). An increase in anxiety-related 
behavior has also been found in other animal models for anxiety, 
such as the light/dark emergence test (Holmes et al., 2001), and the 
mouse four-plate test (Hascoet et al., 1997). Further investigation 
showed this effect to be independent of treatment with BDZs on 
the first trial, and it can be found with inter-trial intervals from 24 h 
up to 14 days (File et al., 1990; Rodgers et al., 1992; Rodgers and 
Shepherd, 1993). Environmental changes, e.g., lighting condition, 
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that the measurements of the anxiety level change in valence (i.e., 
from anxiety to fear) across the two sessions, further indicating an 
emotional shift (File, 1993; File and Zangrossi Jr., 1993; Holmes 
and Rodgers, 1998; Albrechet-Souza et al., 2008). The analysis of so 
called “novel” ethological parameters, i.e., head dips, rearing, and 
risk assessment, adds an additional dimension to the behavioral 
profile shown on both exposures to the plus-maze and allows for 
further evidence for the shift in the affective state of the animal 
(File and Zangrossi Jr., 1993; Rodgers et al., 1996).
Another aspect is the knowledge which is gained during the 
first trial. In the course of exploring the entire maze the animal 
loses the acute approach/avoidance conflict it has initially shown 
(Rodgers and Shepherd, 1993). However, when introducing an 
aversive stimuli in the closed arms on trial 1, Pereira et al. (1999) 
could retain a motivational conflict situation, which resulted in an 
anxiolytic-like effect (i.e., increased open arm time) when treated 
with BDZs. This evidence points to a spatial as well as an emotional 
learning process during the first trial that is responsible for the 
changes in behavior from trial 1 to trial 2 in the EPM (Rodgers 
et al., 1996; Lamprea et al., 2000; Rosa et al., 2000).
The OTT is often taken as one critical evidence that the EPM 
measures two different concepts of aversively motivated behav-
iors upon re-testing and would therefore reflect state- rather than 
trait-anxiety (Andreatini and Bacellar, 2000). On the other hand 
testing EPM behavior is the basis of the established breeding lines 
of high and low anxiety-related behavior Wistar rat lines, which 
show a distinct phenotype profile and point to trait rather than 
state anxiety measured by the EPM (Landgraf and Wigger, 2002). 
Further evidence for measuring trait behavior on the EPM is the 
positive correlation of open arm time measurements in unselected 
Wistar rats between two sessions in the EPM with inter-trial times 
ranging from 24 h up to 120 days (Schwarting and Pawlak, 2004). 
This stability in behavior over time, especially because the open 
arm time recovers after 120 days, supports the categorization into 
high open arm (HOA) and low open arm (LOA) rats (for review 
see Pawlak et al., 2008).
Although the EPM is an economic test paradigm, a simple re-
exposure after 24 h (and even up to 14 days later) presumably 
measures different qualities of aversively motivated behavior. 
While trial 1 is often suggested to reflect a form of anxiety, trial 
2 appears to measure fear-like avoidance behavior in rodents. A 
re-test paradigm which would permit longitudinal studies has 
yet to be established. Such a reliable, valid, and easy to use re-test 
paradigm would substantially widen the advantages of the EPM 
test by allowing a re-exposure of rats to the EPM without eliciting 
the OTT phenomenon. Thus, it was the aim of our experiments 
to obtain results comparable to the behavior of the first trial. We 
hypothesized that the combination of a prolonged inter-trial time 
and a change of the testing environment would abolish the OTT 




Male out bred Wistar Unilever rats weighing 220–249 g each were 
obtained from Harlan (Eystrup, Netherlands) and allowed to habit-
uate for 2 weeks after arrival at the lab. The animals were housed in 
groups of four under a light/dark 12 h cycle (lights on from 0800 
to 2000 h) with free access to food and water. All experiments were 
conducted in accordance with the ethical guidelines for the care and 
use of laboratory animals, and were approved by the local animal 
care committee (AZ: 35-9185.81/G-107/07; Regierungspraesidium 
Karlsruhe, Germany).
apparatus
The EPM was made of dark gray PVC consisting of two opposite 
open arms (50 cm × 12 cm) and two opposite closed arms sur-
rounded by 50 cm high walls of the same dimensions. The middle 
section that allows the animal to transit from arm to arm con-
sisted of a square with dimensions of 12 × 12 cm. The maze was 
elevated 50 cm above ground and the open arms were equipped 
with 0.5 × 0.5 cm ledges to ensure that no animals would fall off 
the maze. The apparatus could be moved between rooms and it 
was made sure that placement and lighting conditions were iden-
tical for each trial. The trials were video recorded and computer 
analyzed with the ethological software viewer2 (Biobserve GmbH, 
Bonn, Germany) to measure time spent in and visits to the arms 
of the EPM. All other ethological analyses were performed by an 
experienced observer. The PC equipment was located outside of 
the experimental rooms. All experiments were carried out during 
the middle of the light phase between 1100 and 1600 h.
drug
Midazolam (ratiopharm, Ulm, Germany) was obtained as solution 
suitable for injection and freshly diluted as needed with 0.9% saline. 
All solutions were administered intraperitoneally (i.p.) 30 min prior 
to the EPM trial in a volume of 1 ml/kg.
procedure
All trials were carried out under low light conditions (30 lux 
white light in the center of the maze) in either of two unfamil-
iar experimental rooms. Room 1 (R1) and Room 2 (R2), which 
mainly differed in size, with R2 being the larger one, but with the 
same basic make-up (white walls, identical light equipment, and 
comparable room equipment). Both experimental rooms were 
similarly distanced from the animal housing room. Each rat was 
gently placed in the center of the maze always facing the same open 
arm. All trials lasted 5 min each allowing the rat to freely explore 
the EPM. Between each animal the maze was thoroughly cleaned 
with a 30% ethanol solution and dried afterward. All experiments 
were carried out by the same experimenter which has been shown 
to be critical in reducing data variability (Chesler et al., 2002; 
Wahlsten et al., 2003).
pIlot experIMent
Two groups of 18 drug-naive rats each were tested on the EPM 
(trial 1) in the room later referred to as R2 (see Experiment 2: 
Switched room). After the first trial the animals were returned to 
the housing room and remained there for 14 days. Following this 
time period each group of animals was again tested on the EPM 
for a second trial: one group was tested again in the same room 
(R2), and the other group in a new testing room later referred to 
as R1 (see Experiment 1: Same room). The animals were tested 
drug free on both trials.
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The dose–response data was analyzed by two-tailed unpaired 
t-tests against the control group and the significance level was 
Bonferroni corrected to adjust for the increasing α-error of mul-
tiple testing (P < 0.017).
results
pIlot experIMent
To assess the effect of an environmental change on EPM anxiety-
like behavior in re-test trial 2 following day 14 after trial 1, testing 
was carried out in either the same or an unfamiliar room. Under 
both conditions a significant decrease in open arm exploration was 
observed in the room change group (post hoc P = 0.01) and without 
change in room (post hoc P < 0.001) between trial 1 and 2 [room 
change: F
(1,34)
 = 1.76, P = 0.19; trial: F
(1,34)
 = 22.15, P < 0.001; interac-
tion: F
(1,34)
 = 0.30, P = 0.59]. A similar effect was not found for closed 
arm visits, [room change: F
(1,34)
 = 1.28, P = 0.27; trial: F
(1,34)
 = 2.42, 
P = 0.13; interaction: F
(1,34)
 = 0.44, P = 0.51; Figure 1].
The relationship between the open arm time measures in both 
trials was significant in the animals which were re-tested in the 
unfamiliar room (r = 0.48, P = 0.04), and as a trend in the group 
tested twice in the same room (r = 0.44, P = 0.07).
dose–response experIMent
Due to the fact that a variety of concentrations of midazolam are 
cited in the available literature it was prudent to test for the effec-
tive dose in our set up (i.e., light condition) of the EPM. Of the 
three tested concentrations only the 0.25-mg/kg dose appeared 
to be anxiolytic. In fact, the higher doses (0.5 and 1.0 mg/kg) had 
an increasingly sedative effect in that a high number of animals 
fell off the maze during the open arm exploration. Statistical test-
ing revealed an anxiolytic effect only between saline controls and 
0.25 mg/kg [t
(13)
 = −2.85; P = 0.01; Figure 2].
experIMent 1: saMe rooM
The effect of the 28-days time span between trials conducted in 
the same room showed no significant changes in the percentage of 
time on the open arms [ANOVA: trial 1 vs. 2: F
(1,18)
 = 2.84, P = 0.11; 
dose–response experIMent
The initial dose–response experiment was carried out with a sepa-
rate group of 32 Wistar rats. The drug-naive animals were ran-
domly assigned into the four treatment groups (n = 8) receiving 
either 0.25, 0.5, 1.0 mg/kg, or saline. The trials were carried out in 
the room which is referred to as R1 in the following experiments. 
Following this 0.25 mg/kg was used in the subsequent EPM experi-
ments as the most effective dose.
experIMent 1: saMe rooM
A group of 20 drug-naive rats were tested on the EPM in room 1 
(R1). After this first trial the animals were brought back into the 
housing room and remained there for 28 days. Following this time 
period the animals were allocated into the midazolam treatment 
group (M-R1; n = 10), and the control group (S-R1; n = 10) which 
received a saline solution. The groups were matched for the open 
arm time measured in trial 1 to ensure equal variation in the treat-
ment groups. The rats were injected 30 min before re-exposure 
to the EPM. This second trial was conducted in the same R1 as 
in trial 1.
experIMent 2: swItched rooM
Another group of drug-naive rats (n = 20) was tested on the EPM 
in R1 for the first trial. As described in Experiment 1, the ani-
mals were allocated into the midazolam treatment group (M-R2; 
n = 10), and the control group (S-R2; n = 10), which received a 
saline solution. This time, however, the second trial was conducted 
in another room (R2), the switched room, to which the animals 
had previously not been exposed. All rats were injected 30 min 
before re-exposure.
BehavIoral analysIs
The standard measurements such as the time spent in the open arms 
and the number of entries in either the open or the closed arms 
were automatically analyzed by the software viewer2 (Biobserve 
GmbH, Bonn, Germany). Entries were counted when all four paws 
had crossed into one of the arms. Horizontal locomotor activity 
is expressed as the number of closed arm entries and the actual 
distance (cm) covered by the animal in the entire maze. Percentage 
of time spent on the open arms was calculated as percentage of the 
total time the rat spent on the maze [open arm time % = 100 × (OA 
time/total time)]. Other behavioral variables such as the frequency 
of rearings (rat stood on its hind paws, raised both forepaws off 
the ground and ended when at least one forepaw had reached the 
floor again), head dips (dipping the head below the open arm of 
the EPM, with all four paws on an open arm), and risk assessment 
(at least one paw remains in a closed arm while nose and eyes 
cross into one of the open arm) were analyzed by an experienced 
experimenter blind to the treatment condition.
statIstIcs
The comparisons between the two trials in the pilot experiment, 
Experiment 1, and Experiment 2, respectively, were performed with 
repeated measures two-way ANOVAs and Tukey post hoc compari-
sons. Pearson’s correlations were used to test for individual relation-
ships between trials. Data are expressed as mean + SEM. All P-values 
are taken as statistically significant when P ≤ 0.05.
A B
FigurE 1 | Difference in (A) open arm time (%) and (B) number of visits 
into the closed arms in two groups of drug-naive rats tested on trial 2 
(day 14) in either the same room or with a room change. (n = 18 in each 
group) ***P < 0.001, **P < 0.01.
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the emotional state in trial 2 did not differ from trial 1 in either 
the saline or midazolam treated animals for risk assessment [trial: 
F
(1,18)
 = 3.48, P = 0.08; treatment: F
(1,18)
 = 0.32, P = 0.58; interac-
tion: F
(1,18)
 = 0.01, P = 0.89], and head dips [trial: F
(1,18)
 = 1.29, 
P = 0.271; treatment: F
(1,18)
 = 0.41, P = 0.53; interaction: F
(1,18)
 = 0.54, 
P = 0.47; Figure 3].
experIMent 2: swItched rooM
Compared to trial 1, the additional change in room on trial 2 
to the inter-trial time of 28 days showed a significant increase 
in percentage of time spent on the open arms in the mida-
zolam treated animals (M-R2 post hoc P = 0.05), while the saline 
treated group (S-R2 post hoc P = 0.31) was unaffected [trial: 
F
(1,18)
 = 4.96, P = 0.04; treatment: F
(1,18)
 = 0.35, P = 0.56; interac-
tion: F
(1,18)
 = 0.55, P = 0.47]. The explorative activity, as measured 
in closed arm entries, was significantly elevated only in the mida-
zolam treated group [post hoc: M-R2 P = 0.14; S-R2 P = 0.02; trial: 
F
(1,18)
 = 8.09, P = 0.01; treatment: F
(1,18)
 = 1.97, P = 0.18; interaction: 
F
(1,18)
 = 0.47, P = 0.50]. While the distance covered revealed no sig-
nificant changes between trials [trial: F
(1,18)
 = 1.65, P = 0.22; treat-
ment: F
(1,18)
 = 0.03, P = 0.86; interaction: F
(1,18)
 = 0.01, P = 0.94]. 
The rearing count was reduced significantly in both groups on 
trial 2 [post hoc M-R2 P = 0.01, trial 1: 10.70 ± 0.60; trial 2: 
6.80 ± 0.71; S-R2 P < 0.001, trial 1: 13 ± 0.97; trial 2: 7.40 ± 0.96; 
trial: F
(1,18)
 = 24.817, P < 0.001; treatment: F
(1,18)
 = 4.70, P = 0.04; 
interaction: F
(1,18)
 = 0.79, P = 0.38]. Risk assessment behavior 
remained unchanged between trials in both treatment groups 
[trial: F
(1,18)
 = 1.78, P = 0.20; treatment: F
(1,18)
 = 0.52, P = 0.48; 
interaction: F
(1,18)
 = 2.61, P = 0.12]. However, the analysis of the 
number of head dips below the level of the open arms revealed a 
significantly increase in the M-R2 group (post hoc P = 0.003) on 
trial 2, while no difference was found in the S-R2 group [post hoc 
P = 0.79; trial: F
(1,18)
 = 6.97, P = 0.02; treatment: F
(1,18)
 = 0.10, 
P = 0.75; interaction: F
(1,18)
 = 5.15, P = 0.04; Figure 4].
treatment saline vs. midazolam: F
(1,18)
 = 0.05, P = 0.83; interaction 
effect: F
(1,18)
 = 0.36, P = 0.56]. The locomotor activity did not differ 
significantly between trials in both treatment groups after post hoc 
comparison [M-R1 P = 0.20; S-R1 P = 0.11; trial: F
(1,18)
 = 4.05, 
P = 0.11; treatment: F
(1,18)
 = 0.01, P = 0.93; interaction: F
(1,18)
 = 0.06, 
P = 0.81]. Similarly the closed arm visits remained statistically non-
significant for both treatment groups [trial: F
(1,18)
 = 1.40, P = 0.25; 
treatment: F
(1,18)
 = 0.07, P = 0.79; interaction: F
(1,18)
 = 1.13, P = 0.30], 
while the rearing activity was significantly decreased only in the 
control animals [post hoc S-R1 P = 0.03, trial 1: 11.70 ± 0.99; trial 2: 
8.00 ± 1.18; M-R1 P = 0.08, trial 1: 11.70 ± 1.39, trial 2: 8.80 ± 1.03; 
trial: F
(1,18)
 = 8.850, P = 0.008; treatment: F
(1,18)
 = 0.11, P = 0.74; 
interaction: F
(1,18)
 = 0.13, P = 0.72]. Additional parameters to assess 
FigurE 2 | Dose–response of three different doses of midazolam and 
saline controls on the open arm time (%) of trial 1 on the EPM. Due to 
increased sedative action of the treatment the number of animals which 
completed a 5-min trial without falling off the maze decreased (saline n = 8; 
0.25 mg n = 7; 0.5 mg n = 5; 1.0 mg n = 3). *P < 0.017.
A B C
FigurE 3 | Treatment effects in trial 2 (dark bars) in the EPM test compared to trial 1 (open bars) in the same room (r1) on (A) the percentage of time spent 
in the open arms, (B) explorative activity measured as track length on the entire maze, and (C) ethological behaviors, i.e., count of risk assessment, head 
dips, and rearings. Each animal was injected before the second trial with either saline (S-R1) or midazolam (M-R1; 0.25 mg/kg), with n = 10 in each group. *P < 0.05.
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Most importantly, the increase of the percentage of time spent 
on the open arms found only in the animals treated with mida-
zolam (0.25 mg/kg) in Experiment 2 suggests that benzodiazepines 
do not lose their anxiolytic-like effects upon re-testing in the EPM. 
Furthermore, the saline treated groups of either testing condi-
tion showed no significant decrease in open arm time. Moreover, 
only in the switched room condition did the midazolam group 
show a positive correlation between both trials, indicating that 
the relative open arm times were comparable between trials and 
also on an individual level. Our testing paradigm to introduce 
an environmental change outside of the EPM apparatus instead 
of using proximal cues (Pereira et al., 1999) appears suitable as a 
quick and easy way for the prevention of the OTT. The increased 
open arm exploration, i.e., time spent on the open arms and head 
dips over the edges, is part of the usual effect of benzodiazepines, 
when given before trial 1.
correlatIons Between trIals
To further analyze the relation between trial 1 and 2, correlation 
coefficients of conventional and the assessed ethological measure-
ments of EPM behaviors are summarized in Table 1. The rationale 
for these analyses is the exploration of the reliability of individ-
ual behaviors between trials within each group and therefore to 
improve the construct validity of this re-test paradigm.
The percentage of time spent in and the number of visits into 
the open arms were highly correlated in the control animals in 
Experiment 1, but not in the midazolam treated group. Furthermore, 
only the saline treated group of rats showed significant correlation 
of ethological measures between trial 1 and 2. Formal measures of 
activity, i.e., visits into the closed arms and rearing behavior, did 
not show significant relationships except for the midazolam treated 
animals in Experiment 1. In Experiment 2, both treatment groups 
showed a significant positive correlation of the percentage of time 
spent in the open arms between trial 1 and trial 2. There were 
significant correlations found within the measure of risk assess-
ing behavior, again in both treatment groups, when the room was 
changed in trial 2.
dIscussIon
The results of both experiments show that an inter-trial interval 
of 28 days alone appears sufficient for a stable response upon 
re-testing in Wistar rats when treated with saline before trial 2 
of the EPM. An extension of inter-trial intervals has previously 
been shown by us to re-instate the reactivity to the EPM to initial 
levels in terms of time spent on the open arms. In the study of 
Schwarting and Pawlak (2004) a period of 120 days between tri-
als not only recovered the OA time but also showed a significant 
correlation between the two trials. Nevertheless, it is important 
to note that this period can apparently be reduced to 28 days as 
shown in the present study.
A B C
FigurE 4 | Treatment effects in trial 2 (dark bars) in the EPM compared to a different testing room (r2) in trial 1 (light bars) on (A) the percentage of time spent 
in the open arms, (B) explorative activity measured as track length on the entire maze, and (C) ethological behaviors, i.e., count of risk assessment, head dips, 
and rearings. Each animal was injected before the second trial with either saline (S-R2) or midazolam (M-R2; 0.25 mg/kg), with n = 10 in each group. **P < 0.01, *P < 0.05.
Table 1 | Correlations between trial 1 and trial 2 EPM measures: effects 
of midazolam (0.25 mg/kg) or saline on trial 2 for both experiments.
Trial 1/2 Experiment 1 Experiment 2 
 (same) (switch)
 S-r1 M-r1 S-r2 M-r2
OA time % 0.857** 0.428 0.596* 0.559*
OA visits 0.910** 0.196 0.217 0.457
CA visits −0.084 0.625* 0.263 0.476
Rearings 0.085 0.088 −0.517 0.037
Risk assessment −0.491 0.472 0.559* 0.551*
Head dips 0.719** 0.274 0.405 0.516
Grooming 0.186 0.000 −0.371 0.229
Pearson correlation coefficient (one-tailed) **P < 0.01, *P < 0.05.
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seen in the control animals of the R2-group (switched room). In 
both experiments, the behavior of the control groups appears to 
be stable over time and on an individual level supporting previous 
studies reporting trait-anxiety-like behavior in a re-test paradigm 
(Schwarting and Pawlak, 2004; Pawlak et al., 2008). It is important 
to note that even though the individuals showed a significant cor-
relation of time spent on the open arms in test/re-test situations 
in HOA and LOA Wistar rats, a marked decrease of open arm 
exploration was occurring within 24 h. This was recovered only 
then a second animal group was exposed to the EPM a 120-days 
after the first trial (Schwarting and Pawlak, 2004).
In the pilot experiment using only untreated rats, the combina-
tion of an inter-trial delay of 14 days (a period in which the OTT 
is still in effect, File, 1993) and a change in testing rooms was not 
sufficient to maintain the baseline level of exploration on the open 
arms shown in trial 1. Even though Figure 1A shows a slight increase 
of open arm time in the switched room group compared to the 
same room group, this was not found to be statistically significant. 
However, the change in room appeared to amplify the correlative 
relationship between the trials, indicating a recovery of a stable 
level of open arm exploration on an individual level as was seen in 
the subsequent experiments when trial 2 was carried out 28 days 
after trial 1. Additionally, the fact that with exception of the M-R2 
group the general locomotor activity remained unchanged across 
the testing conditions with 14 days as well as 28 days between trials, 
suggests that changes in open arm time exploration are not due to 
a general activation of locomotion. Moreover, both rooms used in 
this study are regularly employed when using the EPM and yield 
comparable results.
The results of the present study could imply a change in memory 
retrieval on trial 2 and therefore the perception of the EPM over a 
time course longer than 14 days. Even though it could be argued 
that the decreased rearing activity across all treatment groups and 
test situations implies the recognition of the maze itself, as rearing 
has been suggested to show reactivity to new stimuli (Pawlak and 
Schwarting, 2002).
Additionally, the measurements of other and more complex 
ethological relevant parameters (risk assessment and head dips) 
show similar treatment effects of midazolam on trial 2 after 
28 days of delay to an initial treatment on the first trial (Albrechet-
Souza and Brandao, 2010). The inclusion of these so called “novel” 
ethological measurements allows for a broader assessment of the 
behavioral repertoire shown in trial 1/trial 2 protocol. In view 
of re-instating the initial situation, the additional emotional 
dimensions should be considered. It has been shown that these 
measurements load differently on independent factors in re-test 
paradigms with 24–48 h inter-trial delays (File and Zangrossi Jr., 
1993; Albrechet-Souza et al., 2008) indicating that the behavio-
ral profile of the rodent changes: Shifting from unconditioned 
anxiety to learned avoidance/fear. Our results show significant 
correlations of risk assessing behavior in both treatment groups 
in the switched room testing condition (M-R2 and S-R2), but not 
when the EPM was re-tested in the same room. This implicates 
strongly that the motivational conflict between approaching the 
unknown areas and avoiding potentially dangerous open arms is 
re-instated in trial 2 and is dependent on the changed environ-
ment of Experiment 2.
It has been frequently reported that benzodiazepines lose 
their efficacy when injected before trial 2 (File and Zangrossi 
Jr., 1993; Rodgers and Shepherd, 1993; Cruz-Morales et al., 2002). 
An emotional shift in the animal has been suggested as a prob-
able explanation; the rodent switches from initial exploration of 
the maze to learned avoidance of the open arms even during the 
last minutes of the first trial, and shifts into an acquired phobic-
like state during a later, second exposure to the EPM (Lister, 
1987; File, 1993; File and Zangrossi Jr., 1993; Cruz-Morales et al., 
2002). Furthermore, the initial motivational approach/avoidance 
conflict situation is attenuated in a second exposure to the maze 
because the arms have been explored and the avoidance of the 
exposed areas has been learned. Introducing a motivational con-
flict in the second trial, i.e., hot air stream in one closed arm, was 
able to maintain the exploration on the initial level and abolish 
the OTT (Pereira et al., 1999). Our results show that an inter-
trial delay of 28 day combined with a change of room was able 
to retain the anxiolytic-like effects of midazolam on the percent-
age of time spent on the open arms in the M-R2 switched room 
group. In addition, this group showed a substantial correlation 
between both trials for the open arm time percentage underlin-
ing the relation between both trials and indicating stable trait 
behavior. In parallel, we found a stable and correlated behavior 
of both trials in the control animals (S-R2, switched room) with 
no significant decrease of exploration (percentage of open arm 
time, closed arm visits). Previous findings reported that the OTT 
is evident with an inter-trial time of 24 h up to 14 days (File 
et al., 1990), but has never been tested with longer delays to the 
best of our knowledge.
Furthermore, even though there have been reports that the use 
of a different room 3 weeks after the initial exposures allows for 
repeated measures of plus-maze behavior, these reports unfor-
tunately lack sufficient data on an individual level as well as a 
pharmacological validation (Adamec and Shallow, 2000; Adamec 
and Young, 2000). On the other hand the results of a study investi-
gating a 24-h re-test of the EPM under differing conditions found 
the change of laboratory room insufficient to alter the learned 
avoidance of the open arms. It was suggested that the proximal 
cues of the maze itself would overshadow the distal cues of an 
unfamiliar room (Rodgers et al., 1997). The two rooms used in 
this study differed mainly in size, but had no additional cues on 
the walls, and were located in the same direction and distance 
from the keeping rooms of the rats. Taken together, these facts 
make it conceivable that combining the change of the testing 
environment (i.e., rooms) and the period of time between trials 
(here, 28 days) is sufficient to maintain the approach/avoidance 
conflict, and both appear crucial for the abolishment of the OTT. 
This is further supported by the results of Experiment 1 when 
the EPM remained in the original room (R1) for the second trial 
(same condition). Here, the time period between trials alone was 
not able to preserve the anxiolytic-like effects of midazolam and 
therefore did not modify the phenomenon of OTT. Surprisingly, 
the behavior of the control group (S-R1) in trial 2 did not differ 
significantly from the initial measurements taken on trial 1. The 
high number of complex ethological parameters which correlated 
over 28 days inter-trial time could indicate the measurement of 
actual trait-anxiety on the EPM, and was to a lesser extent also 
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In summary, we suggest that a time period of 28 days in 
combination with a change in testing rooms is necessary to 
reliably re-test EPM behavior and to “re-set” the animal’s behav-
ior to a state comparable to trial 1. Therefore, we propose this 
modified EPM procedure for re-testing EPM behavior to be 
applied for any longitudinal study design, especially for testing 
new pharmacological compounds, or after conditional genetic 
manipulations.
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